Trastuzumab Deruxtecan for Breast Cancer NEJM

ต้นทุนประสิทธิผลของการใช้ Trastuzumab ร่วมลำดับแรกในมะเร็งเต้านมระยะ trastuzumab

CONCLUSION: Administering higher doses on a 3-weekly schedule did not compromise the efficacy and safety of trastuzumab in women with HER2-positive MBC, and

trastuzumab Trastuzumab has also been shown to penetrate an impaired blood–brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery Trastuzumab has also been shown to penetrate an impaired blood–brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of

ไอติมเดลี่ควีน Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2